Advertisement
Telegram ads for your business · TCA Media
Monday, 16 November 2026
The main stories.
Advertisement
Telegram ads for your business · TCA Media
Economy

FDA Warns of Vision Loss Risk for Those Taking Ozempic and Its Analogues

The U.S. Food and Drug Administration (FDA) has mandated manufacturers of all GLP-1 class drugs to include a new warning in their instructions.

10 Nov, 17:04Read in Russian

The warning concerns a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to sudden vision deterioration.

NAION develops when blood supply to the front part of the optic nerve is disrupted. As a result, vision may suddenly decline, sometimes irreversibly. The exact causes of the disease are not fully understood.

According to the FDA, cases of NAION have been recorded in patients taking any GLP-1 drugs currently available on the market. However, the regulator emphasizes that a direct link between the medications and the disease has not yet been proven, and the condition itself remains rare.

Advertisement
Telegram ads for your business · TCA Media

The FDA's decision followed a review of clinical trials, real-world patient data, and scientific publications. An analysis of 126 studies involving over 134,000 participants showed that among those taking GLP-1 drugs, there were 6.4 cases of NAION per 100,000 patients annually. For those receiving other treatments or a placebo, this figure was 3.8. Several other observational studies also identified an increased risk.

GLP-1 drugs are used to treat type 2 diabetes and obesity. This group includes, for example, Ozempic and Wegovy by Novo Nordisk, as well as Mounjaro, Zepbound, and Foundayo by Eli Lilly. CNBC has requested comments from both companies.